Clinical Trials Browser

Phase 2 × Suspended × tazemetostat × Clear all

NCT06575686 2026-01-21

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2 Suspended

Lymphoma, Follicular